Ensysce Biosciences Inc
NASDAQ:ENSC

Watchlist Manager
Ensysce Biosciences Inc Logo
Ensysce Biosciences Inc
NASDAQ:ENSC
Watchlist
Price: 1.055 USD 1.44%
Market Cap: 3.7m USD

Ensysce Biosciences Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ensysce Biosciences Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Ensysce Biosciences Inc
NASDAQ:ENSC
Net Income (Common)
-$11m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Ensysce Biosciences Inc
Glance View

Market Cap
3.7m USD
Industry
Biotechnology

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California. The company went IPO on 2017-12-01. The firm is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. Ensysce’s products include PF614 and PF614- Multi-Pill Abuse Resistant (MPAR). PF614 is a Trypsin-Activated Abuse Protection (TAAP) oxycodone prodrug that is a biologically inactive compound which can be metabolized in the body to produce a drug with demonstrable features aimed at resisting both oral and non-oral modes of prescription drug abuse. TAAP technology seeks to remove the ability of a user to abuse PF614 intravenously or intra-nasally. PF614-MPAR is a combination product of PF614 and nafamostat has designed to limit abuse potential by providing resistance to use through injection or inhalation and to provide overdose protection against excessive oral ingestion. Ensysce initiated a Phase I clinical trial for PF614-MPAR to evaluate safety and Pharmacokinetics in healthy.

ENSC Intrinsic Value
Not Available

See Also

What is Ensysce Biosciences Inc's Net Income (Common)?
Net Income (Common)
-11m USD

Based on the financial report for Sep 30, 2025, Ensysce Biosciences Inc's Net Income (Common) amounts to -11m USD.

What is Ensysce Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
29%

Over the last year, the Net Income (Common) growth was -38%. The average annual Net Income (Common) growth rates for Ensysce Biosciences Inc have been 29% over the past three years .

Back to Top